Maureen Sauvé Receives Messenger of Hope Award from U.S. Scleroderma Foundation
July 30th in New Orleans, Louisiana
The National Board of Directors of the Scleroderma Foundation – the preeminent American organization serving the needs of persons with scleroderma – selected Maureen to receive the award because of her extensive volunteer efforts to “foster greater awareness about scleroderma, not only in Canada and the United States, but, indeed, globally.” In particular, the foundation cited Maureen's advocacy of patient support services, novel research and international collaborations among scleroderma organizations.
Maureen has been active in the scleroderma community since her own diagnosis in 2002. She served as the president of the Scleroderma Society of Ontario from 2008 to 2015, and as president of the Scleroderma Society of Canada (SSC) from 2010 to 2015. Some of her key accomplishments include establishing the SSC national office in Hamilton and she helped establish partnerships with the Scleroderma Foundation and Scleroderma Research Foundation in developing the international Hard word. Harder disease campaign. In 2014, the Canadian Organization for Rare Diseases presented Maureen with the Rare Honour Award for her work in the rare-disease community.
Robert J. Riggs, chief executive officer of the Scleroderma Foundation, said, “Maureen’s contributions show the power that one person can have to impact a community and a cause. She has distinguished herself as an international face of this rare disease, winning the respect of researchers, patients, caregivers, and nonprofit colleagues around the globe.”
Collaboration between Scleroderma Society of Canada, FESCA, and Boehringer Ingelheim
In April, the Scleroderma Society of Canada and FESCA signed an agreement with Boehringer Ingelheim with the intention of working together to advance clinical research and improve awareness of systemic sclerosis (SSc) also known as scleroderma.
Called a Memorandum of Understanding, and written with the assistance and moderation of Eurordis, this agreement is not legally binding and is designed to be fully transparent to everyone. Its immediate goal is to include further patient expertise in the follow-through of a new ongoing trial called SENSCIS, which has been designed to understand if a drug approved for treatment of idiopathic lung fibrosis could also provide a benefit for patients with interstitial lung disease associated with SSc.
Support our mission with a charitable donation and enjoy the tax benefits. We have a number of giving opportunities for you to choose from.